Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
P13349
UPID:
MYF5_HUMAN
Alternative names:
Class C basic helix-loop-helix protein 2
Alternative UPACC:
P13349; Q6ISR9
Background:
Myogenic factor 5, also known as Class C basic helix-loop-helix protein 2, is a pivotal transcriptional activator in muscle differentiation. It promotes the transcription of muscle-specific genes by co-occupying the muscle-specific gene promoter core region alongside MYOG and MYOD1. This protein not only plays a crucial role in myogenesis but also induces fibroblasts to differentiate into myoblasts, showcasing its probable sequence-specific DNA-binding capability.
Therapeutic significance:
Myogenic factor 5 is linked to Ophthalmoplegia, external, with rib and vertebral anomalies, a disorder stemming from gene variants affecting this protein. Understanding the role of Myogenic factor 5 could open doors to potential therapeutic strategies for this autosomal recessive disorder, characterized by congenital nonprogressive external ophthalmoplegia, ptosis, scoliosis, torticollis, and vertebral and rib anomalies.